News">
A devastating blow has been dealt to families battling pediatric brain cancer, as the U.S.federal government has ceased $4 million in annual funding to the Pediatric Brain Tumor Consortium (PBTC). The decision, announced by the National Cancer Institute, prevents the PBTC from applying for another five-year funding cycle beyond March 2026, potentially halting vital research and clinical trials.
A Family’s lost Time, and a Looming Crisis
The impact of this funding cut hits home with the story of Aryeh, a 12-year-old boy who, against all odds, experienced an unexpected week of renewed consciousness after a long illness. His mother recounts cherished moments during that time, a brief reprieve made all the more poignant by the rarity and aggressive nature of his cancer, Anaplastic Pleomorphic Xanthoastrocytoma (APXA). Aryeh endured numerous surgeries, radiation treatments, and experimental medications, but ultimately succumbed to the disease in March 2023.
This personal tragedy underscores the importance of the PBTC’s work, which focuses on early-phase trials evaluating novel therapies for high-risk pediatric brain cancers. The PBTC, founded in 1999, currently manages six active trials, five of which are directly focused on treatment. These trials are crucially important, as standard treatments ofen fall short for rare and aggressive forms of the disease.
what is the Pediatric Brain Tumor Consortium?
The PBTC is a collaborative network of 15 leading academic centers and children’s hospitals. Its mission is to accelerate the growth of new therapies and treatment strategies for children and young adults with brain tumors. This involves conducting phase I and phase II clinical trials, which are essential for evaluating the safety and efficacy of promising new drugs and procedures.
| Organization | Founded | Focus | Current Status |
|---|---|---|---|
| Pediatric Brain Tumor Consortium (PBTC) | 1999 | Pediatric Brain Cancer Research and Trials | Funding halted (Effective March 2026) |
| National Cancer Institute (NCI) | 1937 | Cancer Research and Funding | Reduced Funding for PBTC |
Promising Therapies at Risk
Among the trials jeopardized by the defunding is a neurosurgical procedure using lasers to destroy brain tumors, spearheaded by Dr. Mark Souweidane at NewYork-Presbyterian Hospital/Weill Cornell medical Center and Memorial Sloan Kettering Cancer center. Furthermore, research into cutting-edge therapies like CAR-T cell therapy, showing promising results in conditions like glioblastoma and Diffuse Intrinsic Pontine Glioma (DIPG), may be significantly slowed.
Recent studies have demonstrated encouraging results with CAR-T cell therapy; in a stanford Medicine trial, 11 patients with DIPG received CAR-T cell treatment, with four experiencing tumor shrinkage and one patient remaining cancer-free four years after diagnosis. A separate study explored convection-enhanced delivery, a novel method for bypassing the blood-brain barrier to deliver chemotherapy directly to tumors – demonstrating promising results in children with DIPG, with some patients living over three years after treatment.
Did You No? DIPG, a particularly aggressive form of brain cancer, historically has a median survival rate of just eight to twelve months after diagnosis.
The decision to cut funding has been met with criticism, particularly considering the potential impact on children and families desperately seeking new treatment options. The lost time and opportunities for advancement emphasize the critical need to support pediatric cancer research.
Pro tip: If you are looking for ways to help, consider donating to organizations that support pediatric cancer research and patient support services.
The Landscape of Pediatric Brain Cancer Research
Pediatric brain tumors, while less common than adult brain tumors, represent the most common type of cancer in children. Approximately 4,000 children in the United States are diagnosed with a primary brain tumor each year, according to the American Cancer society. Important progress has been made in recent decades, with survival rates improving for many types of pediatric brain tumors. However, challenges remain, particularly for aggressive and rare tumors like DIPG and APXA.
Frequently Asked Questions about Pediatric Brain Cancer Research
- What is the PBTC? The Pediatric Brain Tumor Consortium is a network of institutions focused on conducting clinical trials for pediatric brain cancer.
- Why has PBTC funding been cut? The U.S. federal government has halted $4 million in annual funding to the consortium.
- What is CAR-T cell therapy? It’s a type of immunotherapy that shows promise in treating aggressive brain cancers such as glioblastoma and DIPG.
- How does convection-enhanced delivery work? This technique bypasses the blood-brain barrier to deliver chemotherapy directly into the tumor.
- What are the typical survival rates for DIPG? Historically, the median survival rate for DIPG is eight to twelve months.
- Where can I find more information about pediatric brain cancer? Visit the National cancer Institute ([https://www.cancer.gov/types/brain](https://www.cancer.gov/types/brain)) and the American Cancer Society ([https://www.cancer.org/cancer/brain-tumors-in-children.html](https://www.cancer.org/cancer/brain-tumors-in-children.html)).
What are your thoughts on the importance of funding for pediatric cancer research? Share your comments below, and share this article to raise awareness about this critical issue.
